Retinal Phenotype of Patients With Isolated Retinal Degeneration Due to CLN3 Pathogenic Variants in a French Retinitis Pigmentosa Cohort.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 03 2021
Historique:
pubmed: 29 1 2021
medline: 30 6 2021
entrez: 28 1 2021
Statut: ppublish

Résumé

Biallelic variants in CLN3 lead to a spectrum of diseases, ranging from severe neurodegeneration with retinal involvement (juvenile neuronal ceroid lipofuscinosis) to retina-restricted conditions. To provide a detailed description of the retinal phenotype of patients with isolated retinal degeneration harboring biallelic CLN3 pathogenic variants and to attempt a phenotype-genotype correlation associated with this gene defect. This retrospective cohort study included patients carrying biallelic CLN3 variants extracted from a cohort of patients with inherited retinal disorders (IRDs) investigated at the National Reference Center for Rare Ocular Diseases of the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts from December 2007 to August 2020. Data were analyzed from October 2019 to August 2020. Functional (best-corrected visual acuity, visual field, color vision, and full-field electroretinogram), morphological (multimodal retinal imaging), and clinical data from patients were collected and analyzed. Gene defect was identified by either next-generation sequencing or whole-exome sequencing and confirmed by Sanger sequencing, quantitative polymerase chain reaction, and cosegregation analysis. Of 1533 included patients, 843 (55.0%) were women and 690 (45.0%) were men. A total of 15 cases from 11 unrelated families harboring biallelic CLN3 variants were identified. All patients presented with nonsyndromic IRD. Two distinct patterns of retinal disease could be identified: a mild rod-cone degeneration of middle-age onset (n = 6; legal blindness threshold reached by 70s) and a severe retinal degeneration with early macular atrophic changes (n = 9; legal blindness threshold reached by 40s). Eleven distinct pathogenic variants were detected, of which 4 were novel. All but 1, p.(Arg405Trp), CLN3 point variants and their genotypic associations were clearly distinct between juvenile neuronal ceroid lipofuscinosis and retina-restricted disease. Mild and severe forms of retina-restricted CLN3-linked IRDs also had different genetic background. These findings suggest CLN3 should be included in next-generation sequencing panels when investigating patients with nonsyndromic rod-cone dystrophy. These results document phenotype-genotype correlations associated with specific variants in CLN3. However, caution seems warranted regarding the potential neurological outcome if a pathogenic variant in CLN3 is detected in a case of presumed isolated IRD for the onset of neurological symptoms could be delayed.

Identifiants

pubmed: 33507216
pii: 2775583
doi: 10.1001/jamaophthalmol.2020.6089
pmc: PMC7844693
doi:

Substances chimiques

CLN3 protein, human 0
Membrane Glycoproteins 0
Molecular Chaperones 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-291

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn

Auteurs

Vasily M Smirnov (VM)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.
Université de Lille, Faculté de Médecine, Lille, France.
Exploration de la Vision et Neuro-Ophtalmologie, CHU de Lille, Lille, France.

Marco Nassisi (M)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.

Cyntia Solis Hernandez (C)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.

Cécile Méjécase (C)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.
Institute of Ophthalmology, University College London, London, United Kingdom.

Said El Shamieh (S)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.
Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.

Christel Condroyer (C)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.

Aline Antonio (A)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.

Isabelle Meunier (I)

Institute for Neurosciences Montpellier, INSERM U1051, University of Monpellier, Montpellier, France.
National Center for Rare Genetic Retinal Dystrophies, Hôpital Guy de Chauliac, Montpellier, France.

Camille Andrieu (C)

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DHOS CIC 1423, Paris, France.

Sabine Defoort-Dhellemmes (S)

Exploration de la Vision et Neuro-Ophtalmologie, CHU de Lille, Lille, France.

Saddek Mohand-Said (S)

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DHOS CIC 1423, Paris, France.

José-Alain Sahel (JA)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DHOS CIC 1423, Paris, France.
Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
Académie des Sciences, Institut de France, Paris, France.
Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Isabelle Audo (I)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.
Institute of Ophthalmology, University College London, London, United Kingdom.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DHOS CIC 1423, Paris, France.

Christina Zeitz (C)

Sorbonne Université, INSERM, Centre national de la recherche scientifique, Institut de la Vision, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH